Physicochemical Properties
| Molecular Formula | C25H26N6O2 |
| Exact Mass | 442.211 |
| CAS # | 1428064-91-8 |
| PubChem CID | 89451003 |
| Appearance | Light brown to khaki solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 607.6±55.0 °C at 760 mmHg |
| Flash Point | 321.3±31.5 °C |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.688 |
| LogP | 2.67 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 33 |
| Complexity | 644 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | YDPWZFPXWFTXNT-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C25H26N6O2/c1-33-23-8-6-20(15-27-23)28-25(32)24-21-12-18(5-7-22(21)29-30-24)19-11-17(13-26-14-19)16-31-9-3-2-4-10-31/h5-8,11-15H,2-4,9-10,16H2,1H3,(H,28,32)(H,29,30) |
| Chemical Name | N-(6-methoxypyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | The human colorectal partner line (SW480) is treated with templovivint (Compound 175; 0.0003-10 μM) to decrease Wnt/p-catenin activity in a dose-regulated manner (EC50=152.9 nM) [1]. = 25 nM) as well as primary hMSCs (EC50=10.377 μM) from human mesenchymal stem cells [1]. With an EC50 ranging from 139 to 189 nM, teplinovivint (5.8, 10.8, 21.7, 41.7, 83.3, 166.6, 333.3, 750 nM) stimulates the expression of SCXA, tenacinC, and tenomoduLin in a dose-dependent manner [1]. |
| ln Vivo | Teplinovivint (Compound 175; 10 mg/mL; given topically once daily for 21 days) reduces inflammation and tendon injury. Teplinovivint causes a decrease in the inflammatory arthritis biomarker KC/GRO in a collagenase-induced muscle damage injury model [1] Teplinovivint (1 mg/mL with 1% BA) had a Tmax of 1 hour in bundles [1]. |
| References |
[1]. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. WO2018075858A1. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~83.33 mg/mL (~188.31 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.70 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |